News roundup Friday, August 16

The latest from BioStock

» Deversify aims for more markets and the next breathalyzer
» CB certificate boosted Neola Medical's Q2
» Lipum's CEO summarizes the first half of the year – continued positive study data
» Deversify Health presents its offering in consumer health
» Cyxone's CEO on the valuation of pharmaceutical projects

The latest news

enters the US capital market through listing on the OTCQB Venture Market in the US. Read more.

Today the subscription period begins in Dicot Pharmas rights issue. Read more.

Cereno Scientific extends patent protection for PAH drug candidate CS1's third patent family in Brazil. Read more.

Cyxone publishes the outcome of the completed rights issue. Read more.

Infant Bacterial Therapeutics Patent approved in the USA. Read more.

BBS-Bioactive Bone Substitutes comments on the CE approval process for the bone replacement product Artebone. Read more.

Scandion Oncology reaches the maximum tolerated dose for CHORUS of 3. Read more.

Bavarian Nordic submits data to EMA to expand approval of the mpox/smallpox vaccine to adolescents. Read more.

AstraZeneca Imfinzi approved in the US for the treatment of resectable lung cancer. Read more.

PharmaLundensis decides on a rights issue of units consisting of shares and warrants. Read more.

The Swedish Companies Registration Office has approved Ecti Research liquidation. The company has also applied for delisting of the company's shares from the Spotlight Stock Market. Read more.

PMD Device Solutions publishes preliminary financial data ahead of Q2. Read more.

Reports

Aino Health  CS Medica  Fluicell  Medistim  Navamedic  Nexstim  PharmaLundensis  Pharma Equity Group  RaySearch Laboratories  SpectraCure (amendment)  ViroGates

Invitation to presentations

ArcticZymes Technologies  Nanoform Finland  SoftOx Solutions  Thor Medical  Vistin Pharma

Summons

Biovica International  Inhalation Sciences

This morning's price development

Index: OMXS30 +0,28% Healthcare + 0,60 %